[1] Zhou B,Zeng S,Li L,et al.Angiogenic factor with G patch and FHA domaing 1(Aggf1) regulates liver fibrosis by modulating TGF-β signaling.Biochim Biophys Acta,2016,1862:1203-1213.
[2] Li D,Guabiraba R,Besnard AG,et al.IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice.J Allergy Clin Immunol,2014, 134:1422.
[3] Baekkevold ES,Roussigné M,Yamanaka T,et al.Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules.Am J Pathol,2003,163:69-79.
[4] Liu X,Hammel M,He Y,et al.Structural insights into the interaction of IL-33 with its receptors.Proc Natl Acad Sci U S A,2013,110: 14918-14923.
[5] Marvie P,Lisbonne M,L′helgoualc′h A,et al.Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med,2010,14:1726-1739.
[6] Griesenauer B,Paczesny S.The ST2/IL-33 axis in immune cells during inflammatory diseases.Frontiers in Immunology,2017,8:475.
[7] Chackerian AA,Oldham ER,Murphy EE,et al.IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.J Immunol,2007, 179:2551-2555.
[8] Schmitz J,Owyang A,Oldham E,et al.IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity,2005,23:479-490.
[9] Lei Z,Mo Z,Zhu J,et al.Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure.Mediators Inflamm,2015,2015:535938.
[10] Dinerello CA.An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor.Immunity,2005,23:461-462.
[11] Drake LY,Kita H.IL-33: biological properties, functions, and roles in airway disease.Immunol Rev,2017,278:173-184.
[12] Lefrancais E,Roga S,Gautier V,et al.IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.Proc Natl Acad Sci U S A,2012,109:1673-1678.
[13] Heymann F, Tacke F.Immunology in the liver--from homeostasis to disease.Nat Rev Gastroenterol Hepatol,2016,13:88-110.
[14] Gao Y,Liu Y,Yang M,et al.IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget,2016,7:33649-33661.
[15] Li J,Razumilava N,Gores GJ,et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation.J Clin Invest,2014,124:3241-3251.
[16] Mchedlidze T,Waldner M,Zopf S,et al.Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis.Immunity,2013, 39:357-371.
[17] Tan Z,Liu Q,Jiang R,et al.Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells.Cell Mol Immunol,2018,15:388-398.
[18] Sun Z,Chang B,Gao M,et al.IL-33-ST2 axis in liver disease: Progression and Challenge. Mediators Inflamm,2017:5314213.
[19] Oztas E,Kuzu UB,Zengin NI,et al.Can serum st2 levels be used as a marker of fibrosis in chronic hepatitis B infection?.Medicine,2015,94:e1889. |
